InfuSystem Holdings, Inc. (NYSE:INFU – Get Free Report) Director Kenneth D. Eichenbaum purchased 4,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were acquired at an average cost of $5.89 per share, for a total transaction of $23,560.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $23,560. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
InfuSystem Trading Up 10.2 %
NYSE:INFU opened at $6.57 on Friday. The firm has a market cap of $140.07 million, a P/E ratio of -657,000.00 and a beta of 1.46. InfuSystem Holdings, Inc. has a 52 week low of $5.74 and a 52 week high of $10.99. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.07 and a quick ratio of 1.64.
InfuSystem (NYSE:INFU – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $33.70 million during the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.
Institutional Investors Weigh In On InfuSystem
Analyst Upgrades and Downgrades
Several analysts have weighed in on the stock. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 20th. B. Riley initiated coverage on InfuSystem in a research report on Thursday. They set a “buy” rating and a $13.00 price target on the stock.
View Our Latest Research Report on InfuSystem
About InfuSystem
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Read More
- Five stocks we like better than InfuSystem
- Investing In Automotive Stocks
- Top 3 Homebuilder Stocks to Watch as Rates Drop
- How to buy stock: A step-by-step guide for beginners
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Ride Out The Recession With These Dividend Kings
- KB Home Slips After Earnings: What’s Next for Homebuilders?
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.